Anti-Interleukin 17A Biologic Therapy Attempts on Livedoid Vasculopathy: A Report of Case Series

Fei Qi; Yimeng Gao; Hongzhong Jin

doi:10.2147/CCID.S455903

Anti-Interleukin 17A Biologic Therapy Attempts on Livedoid Vasculopathy: A Report of Case Series

Clin Cosmet Investig Dermatol. 2024 May 9:17:1043-1048. doi: 10.2147/CCID.S455903. eCollection 2024.

Authors

Fei Qi¹, Yimeng Gao¹, Hongzhong Jin¹

Affiliation

¹ Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, 100730, People's Republic of China.

Abstract

The application of biologics such as anti-tumor necrosis factor (TNF) has shown great efficacy in livedoid vasculopathy (LV). However, new biological options need to be identified for those with a high tuberculosis reactivation risk. In this study, we evaluated the efficacy of anti-17A biologics for LV therapy. Two patients with LV who were irresponsive to traditional anticoagulation therapy were studied at the outpatient dermatology clinic of Peking Union Medical College Hospital. All patients received anti-17A biological therapy for at least two-four weeks. Both patients reported an exacerbation of the skin lesions, which might indicate that the IL-17 pathway plays a critical role in LV pathogenesis.

Keywords: IL-17; TNF-alpha; atrophied blanched; biologic therapy; livedoid vasculopathy.

Publication types

Case Reports

Grants and funding

1. National High Level Hospital Clinical Research Funding (2022-PUMCH-B-092). 2. National Natural Science Foundation of China (82073450). 3. National Key Clinical Specialty Project of China.